2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°Á : 2024-05-18 |
|
2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°Á : 2024-05-18 ±³À°ÁÖÁ¦ : 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°Á ÁÖÃÖ±â°ü : ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ À̸ÞÀÏ : kspho@kams.or.kr ±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú Âü¼®¿¹»óÀÎ : 70¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 50,000¿ø ºñ°í Àü¹®ÀÇ 50,000¿ø, Àü°øÀÇ/°£È£»ç 30,000¿ø
±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 10:30~11:00 2023 ASH review, ALL(acute lymphoblastic leukemia) /lymphoma Á¶¼öÁ¤(°¡Å縯ÀÇ´ë ) ±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 11:00~11:30 2023 ASH review, AML/MDS(acute myeloid leukemia/ myelodysplastic syndrome) ±èº¸°æ(¼¿ïÀÇ´ë ) ±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 11:30~12:00 2023 SIOP review, Recent update of pediatic oncology' ÀÌÀº»ó(°í·ÁÀÇ´ë ) ±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 13:00~13:40 Hemangioma Á¤Çý¸²(¼º±Õ°üÀÇ´ë ) ±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 13:50~14:20 General management of patients with childhood cancers ¼Áø°æ(±¹¸³¾Ï¼¾ÅÍ ) ±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 14:20~14:50 Chemotherapy-induced adverse event management ¾çÀ¯Áø(ºÎ»êÀÇ´ë ) ±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 14:50~15:20 Management of immunotherapy, target agents, and cell therapy associated adverse reaction Á¶Èñ¿ø(¼º±Õ°üÀÇ´ë ) ±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 15:30~16:00 Acute lymphoblastic leukemia À¯Àç¿ø(°¡Å縯ÀÇ´ë ) ±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 16:00~16:30 Acute myeloid leukemia °¼ºÇÑ(¿ï»êÀÇ´ë) ±³À°½Ã°£ 05¿ù 18ÀÏ ÀÌ°ÇÈñȦ 16:30~17:00 Lymphoma ÁÖÈñ¿µ(¼º±Õ°üÀÇ´ë )
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|